1
|
Afewerki S, Stocco TD, Rosa da Silva AD, Aguiar Furtado AS, Fernandes de Sousa G, Ruiz-Esparza GU, Webster TJ, Marciano FR, Strømme M, Zhang YS, Lobo AO. In vitro high-content tissue models to address precision medicine challenges. Mol Aspects Med 2023; 91:101108. [PMID: 35987701 PMCID: PMC9384546 DOI: 10.1016/j.mam.2022.101108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 06/29/2022] [Accepted: 07/20/2022] [Indexed: 01/18/2023]
Abstract
The field of precision medicine allows for tailor-made treatments specific to a patient and thereby improve the efficiency and accuracy of disease prevention, diagnosis, and treatment and at the same time would reduce the cost, redundant treatment, and side effects of current treatments. Here, the combination of organ-on-a-chip and bioprinting into engineering high-content in vitro tissue models is envisioned to address some precision medicine challenges. This strategy could be employed to tackle the current coronavirus disease 2019 (COVID-19), which has made a significant impact and paradigm shift in our society. Nevertheless, despite that vaccines against COVID-19 have been successfully developed and vaccination programs are already being deployed worldwide, it will likely require some time before it is available to everyone. Furthermore, there are still some uncertainties and lack of a full understanding of the virus as demonstrated in the high number new mutations arising worldwide and reinfections of already vaccinated individuals. To this end, efficient diagnostic tools and treatments are still urgently needed. In this context, the convergence of bioprinting and organ-on-a-chip technologies, either used alone or in combination, could possibly function as a prominent tool in addressing the current pandemic. This could enable facile advances of important tools, diagnostics, and better physiologically representative in vitro models specific to individuals allowing for faster and more accurate screening of therapeutics evaluating their efficacy and toxicity. This review will cover such technological advances and highlight what is needed for the field to mature for tackling the various needs for current and future pandemics as well as their relevancy towards precision medicine.
Collapse
Affiliation(s)
- Samson Afewerki
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, BOX 35, 751 03, Uppsala, Sweden
| | - Thiago Domingues Stocco
- Bioengineering Program, Technological and Scientific Institute, Brazil University, 08230-030, São Paulo, SP, Brazil,Faculty of Medical Sciences, Unicamp - State University of Campinas, 13083-877, Campinas, SP, Brazil
| | | | - André Sales Aguiar Furtado
- Interdisciplinary Laboratory for Advanced Materials, BioMatLab, Department of Materials Engineering, Federal University of Piauí (UFPI), Teresina, PI, Brazil
| | - Gustavo Fernandes de Sousa
- Interdisciplinary Laboratory for Advanced Materials, BioMatLab, Department of Materials Engineering, Federal University of Piauí (UFPI), Teresina, PI, Brazil
| | - Guillermo U. Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA,Division of Health Sciences and Technology, Harvard University ‑ Massachusetts Institute of Technology, Boston, MA, 02115, USA
| | - Thomas J. Webster
- Interdisciplinary Laboratory for Advanced Materials, BioMatLab, Department of Materials Engineering, Federal University of Piauí (UFPI), Teresina, PI, Brazil,Hebei University of Technology, Tianjin, China
| | | | - Maria Strømme
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, BOX 35, 751 03, Uppsala, Sweden
| | - Yu Shrike Zhang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA; Division of Health Sciences and Technology, Harvard University ‑ Massachusetts Institute of Technology, Boston, MA, 02115, USA.
| | - Anderson Oliveira Lobo
- Interdisciplinary Laboratory for Advanced Materials, BioMatLab, Department of Materials Engineering, Federal University of Piauí (UFPI), Teresina, PI, Brazil.
| |
Collapse
|
2
|
Lopez-Cantu DO, Wang X, Carrasco-Magallanes H, Afewerki S, Zhang X, Bonventre JV, Ruiz-Esparza GU. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nanomicro Lett 2022; 14:41. [PMID: 34981278 PMCID: PMC8722410 DOI: 10.1007/s40820-021-00771-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 11/12/2021] [Indexed: 05/02/2023]
Abstract
During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have been positioned as solutions to mitigate the pandemic outbreak caused by the novel pathogen severe acute respiratory syndrome coronavirus 2. To fast-track the development of vaccines, unprecedented industrial and academic collaborations emerged around the world, resulting in the clinical translation of effective vaccines in less than one year. In this article, we provide an overview of the path to translation from the bench to the clinic of nanotechnology-enabled messenger ribonucleic acid vaccines and examine in detail the types of delivery systems used, their mechanisms of action, obtained results during each phase of their clinical development and their regulatory approval process. We also analyze how nanotechnology is impacting global health and economy during the COVID-19 pandemic and beyond.
Collapse
Affiliation(s)
- Diana O Lopez-Cantu
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA
- Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
- Tecnologico de Monterrey, School of Engineering and Sciences, 64849, Monterrey, NL, Mexico
| | - Xichi Wang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA
- Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China
| | - Hector Carrasco-Magallanes
- Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA
- Tecnologico de Monterrey, School of Medicine and Health Sciences, 64849, Monterrey, NL, Mexico
| | - Samson Afewerki
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA
| | - Xingcai Zhang
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
- School of Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
| | - Joseph V Bonventre
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA.
- Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA.
- Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
| |
Collapse
|
3
|
Hernandez JOR, Wang X, Vazquez-Segoviano M, Lopez-Marfil M, Sobral-Reyes MF, Moran-Horowich A, Sundberg M, Lopez-Cantu DO, Probst CK, Ruiz-Esparza GU, Giannikou K, Abdi R, Henske EP, Kwiatkowski DJ, Sahin M, Lemos DR. A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo. Nat Commun 2021; 12:6496. [PMID: 34764250 PMCID: PMC8586030 DOI: 10.1038/s41467-021-26596-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 10/13/2021] [Indexed: 01/03/2023] Open
Abstract
The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test prospective therapies in vivo. Generation of kidney organoids from Tuberous Sclerosis Complex (TSC) patient-derived-hiPSCs allows us to recapitulate a rare kidney tumor called angiomyolipoma (AML). Organoids derived from TSC2-/- hiPSCs but not from isogenic TSC2+/- or TSC2+/+ hiPSCs share a common transcriptional signature and a myomelanocytic cell phenotype with kidney AMLs, and develop epithelial cysts, replicating two major TSC-associated kidney lesions driven by genetic mechanisms that cannot be consistently recapitulated with transgenic mice. Transplantation of multiple TSC2-/- renal organoids into the kidneys of immunodeficient rats allows us to model AML in vivo for the study of tumor mechanisms, and to test the efficacy of rapamycin-loaded nanoparticles as an approach to rapidly ablate AMLs. Collectively, our experimental approaches represent an innovative and scalable tissue-bioengineering strategy for modeling rare kidney disease in vivo.
Collapse
Affiliation(s)
- J O R Hernandez
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - X Wang
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | | | - M Lopez-Marfil
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - M F Sobral-Reyes
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - A Moran-Horowich
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - M Sundberg
- Rosamund Zander Stone Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA
- Harvard Medical School, Boston, MA, 02115, USA
| | - D O Lopez-Cantu
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - C K Probst
- Cancer Genetics Lab, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Center for LAM Research and Clinical Care, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - G U Ruiz-Esparza
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - K Giannikou
- Harvard Medical School, Boston, MA, 02115, USA
- Cancer Genetics Lab, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Center for LAM Research and Clinical Care, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - R Abdi
- Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - E P Henske
- Harvard Medical School, Boston, MA, 02115, USA
- Cancer Genetics Lab, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Center for LAM Research and Clinical Care, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - D J Kwiatkowski
- Harvard Medical School, Boston, MA, 02115, USA
- Cancer Genetics Lab, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Center for LAM Research and Clinical Care, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - M Sahin
- Rosamund Zander Stone Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA
- Harvard Medical School, Boston, MA, 02115, USA
| | - D R Lemos
- Renal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA.
- Harvard Medical School, Boston, MA, 02115, USA.
- Harvard Stem Cell Institute, Cambridge, MA, 02138, USA.
| |
Collapse
|
4
|
Ruiz-Esparza GU, Wang X, Zhang X, Jimenez-Vazquez S, Diaz-Gomez L, Lavoie AM, Afewerki S, Fuentes-Baldemar AA, Parra-Saldivar R, Jiang N, Annabi N, Saleh B, Yetisen AK, Sheikhi A, Jozefiak TH, Shin SR, Dong N, Khademhosseini A. Nanoengineered Shear-Thinning Hydrogel Barrier for Preventing Postoperative Abdominal Adhesions. Nanomicro Lett 2021; 13:212. [PMID: 34664123 PMCID: PMC8523737 DOI: 10.1007/s40820-021-00712-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 08/03/2021] [Indexed: 06/13/2023]
Abstract
More than 90% of surgical patients develop postoperative adhesions, and the incidence of hospital re-admissions can be as high as 20%. Current adhesion barriers present limited efficacy due to difficulties in application and incompatibility with minimally invasive interventions. To solve this clinical limitation, we developed an injectable and sprayable shear-thinning hydrogel barrier (STHB) composed of silicate nanoplatelets and poly(ethylene oxide). We optimized this technology to recover mechanical integrity after stress, enabling its delivery though injectable and sprayable methods. We also demonstrated limited cell adhesion and cytotoxicity to STHB compositions in vitro. The STHB was then tested in a rodent model of peritoneal injury to determine its efficacy preventing the formation of postoperative adhesions. After two weeks, the peritoneal adhesion index was used as a scoring method to determine the formation of postoperative adhesions, and STHB formulations presented superior efficacy compared to a commercially available adhesion barrier. Histological and immunohistochemical examination showed reduced adhesion formation and minimal immune infiltration in STHB formulations. Our technology demonstrated increased efficacy, ease of use in complex anatomies, and compatibility with different delivery methods, providing a robust universal platform to prevent postoperative adhesions in a wide range of surgical interventions.
Collapse
Affiliation(s)
- Guillermo U Ruiz-Esparza
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Xichi Wang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China
| | - Xingcai Zhang
- School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA
| | - Sofia Jimenez-Vazquez
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- School of Engineering and Science, Tecnologico de Monterrey, Campus Monterrey, Monterrey, Nuevo Leon, 64849, Mexico
- School of Medicine and Health Science, Campus Guadalajara, Zapopan, Jalisco, 45201, Mexico
| | - Liliana Diaz-Gomez
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- School of Engineering and Science, Tecnologico de Monterrey, Campus Monterrey, Monterrey, Nuevo Leon, 64849, Mexico
- School of Medicine and Health Science, Campus Guadalajara, Zapopan, Jalisco, 45201, Mexico
| | - Anne-Marie Lavoie
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Samson Afewerki
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Andres A Fuentes-Baldemar
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- School of Engineering and Science, Tecnologico de Monterrey, Campus Monterrey, Monterrey, Nuevo Leon, 64849, Mexico
- School of Medicine and Health Science, Campus Guadalajara, Zapopan, Jalisco, 45201, Mexico
| | - Roberto Parra-Saldivar
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- School of Engineering and Science, Tecnologico de Monterrey, Campus Monterrey, Monterrey, Nuevo Leon, 64849, Mexico
- School of Medicine and Health Science, Campus Guadalajara, Zapopan, Jalisco, 45201, Mexico
| | - Nan Jiang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, 610041, China
| | - Nasim Annabi
- Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA
| | - Bahram Saleh
- Department of Chemical Engineering, Northeastern University, Boston, MA, 02115, USA
| | - Ali K Yetisen
- Department of Chemical Engineering, Imperial College London, London, SW7 2AZ, UK
| | - Amir Sheikhi
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA
- Department of Biomedical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA
| | - Thomas H Jozefiak
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Su Ryon Shin
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Nianguo Dong
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA.
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
- Terasaki Institute for Biomedical Innovation, 11570 W Olympic Blvd, Los Angeles, CA, 90024, USA.
| |
Collapse
|
5
|
Mier A, Maffucci I, Merlier F, Prost E, Montagna V, Ruiz-Esparza GU, Bonventre JV, Dhal PK, Tse Sum Bui B, Sakhaii P, Haupt K. Molecularly Imprinted Polymer Nanogels for Protein Recognition: Direct Proof of Specific Binding Sites by Solution STD and WaterLOGSY NMR Spectroscopies. Angew Chem Int Ed Engl 2021; 60:20849-20857. [PMID: 34296498 PMCID: PMC8562893 DOI: 10.1002/anie.202106507] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 07/15/2021] [Indexed: 11/07/2022]
Abstract
Molecularly imprinted polymers (MIPs) are tailor-made synthetic antibodies possessing specific binding cavities designed for a target molecule. Currently, MIPs for protein targets are synthesized by imprinting a short surface-exposed fragment of the protein, called epitope or antigenic determinant. However, finding the epitope par excellence that will yield a peptide "synthetic antibody" cross-reacting exclusively with the protein from which it is derived, is not easy. We propose a computer-based rational approach to unambiguously identify the "best" epitope candidate. Then, using Saturation Transfer Difference (STD) and WaterLOGSY NMR spectroscopies, we prove the existence of specific binding sites created by the imprinting of this peptide epitope in the MIP nanogel. The optimized MIP nanogel could bind the epitope and cognate protein with a high affinity and selectivity. The study was performed on Hepatitis A Virus Cell Receptor-1 protein, also known as KIM-1 and TIM-1, for its ubiquitous implication in numerous pathologies.
Collapse
Affiliation(s)
- Alejandra Mier
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Irene Maffucci
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Franck Merlier
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Elise Prost
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Valentina Montagna
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Guillermo U Ruiz-Esparza
- Divisions of Engineering in Medicine and Renal Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Division of Health Science and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Joseph V Bonventre
- Divisions of Engineering in Medicine and Renal Medicine, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 02115, USA
- Division of Health Science and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Pradeep K Dhal
- US Early Development, Sanofi Global R&D, 153 Second Avenue, Waltham, MA, 02451, USA
| | - Bernadette Tse Sum Bui
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| | - Peyman Sakhaii
- R&D Global CMC Development-Synthetics-Early Development Frankfurt, Sanofi-Aventis (Deutschland) GmbH, Industriepark Hoechst, Frankfurt am Main, Germany
| | - Karsten Haupt
- CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France
| |
Collapse
|
6
|
Wang X, Liu Z, Sandoval-Salaiza DA, Afewerki S, Jimenez-Rodriguez MG, Sanchez-Melgar L, Güemes-Aguilar G, Gonzalez-Sanchez DG, Noble O, Lerma C, Parra-Saldivar R, Lemos DR, Llamas-Esperon GA, Shi J, Li L, Lobo AO, Fuentes-Baldemar AA, Bonventre JV, Dong N, Ruiz-Esparza GU. Nanostructured Non-Newtonian Drug Delivery Barrier Prevents Postoperative Intrapericardial Adhesions. ACS Appl Mater Interfaces 2021; 13:29231-29246. [PMID: 34137251 DOI: 10.1021/acsami.0c20084] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
With the increasing volume of cardiovascular surgeries and the rising adoption rate of new methodologies that serve as a bridge to cardiac transplantation and that require multiple surgical interventions, the formation of postoperative intrapericardial adhesions has become a challenging problem that limits future surgical procedures, causes serious complications, and increases medical costs. To prevent this pathology, we developed a nanotechnology-based self-healing drug delivery hydrogel barrier composed of silicate nanodisks and polyethylene glycol with the ability to coat the epicardial surface of the heart without friction and locally deliver dexamethasone, an anti-inflammatory drug. After the fabrication of the hydrogel, mechanical characterization and responses to shear, strain, and recovery were analyzed, confirming its shear-thinning and self-healing properties. This behavior allowed its facile injection (5.75 ± 0.15 to 22.01 ± 0.95 N) and subsequent mechanical recovery. The encapsulation of dexamethasone within the hydrogel system was confirmed by 1H NMR, and controlled release for 5 days was observed. In vitro, limited cellular adhesion to the hydrogel surface was achieved, and its anti-inflammatory properties were confirmed, as downregulation of ICAM-1 and VCAM-1 was observed in TNF-α activated endothelial cells. In vivo, 1 week after administration of the hydrogel to a rabbit model of intrapericardial injury, superior efficacy was observed when compared to a commercial adhesion barrier, as histological and immunohistochemical examination revealed reduced adhesion formation and minimal immune infiltration of CD3+ lymphocytes and CD68+ macrophages, as well as NF-κβ downregulation. We presented a novel nanostructured drug delivery hydrogel system with unique mechanical and biological properties that act synergistically to prevent cellular infiltration while providing local immunomodulation to protect the intrapericardial space after a surgical intervention.
Collapse
Affiliation(s)
- Xichi Wang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Zongtao Liu
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Diego A Sandoval-Salaiza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Samson Afewerki
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Mildred G Jimenez-Rodriguez
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Lorena Sanchez-Melgar
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Gabriela Güemes-Aguilar
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Medicine and Health Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - David G Gonzalez-Sanchez
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Medicine and Health Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Oscar Noble
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Medicine and Health Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Cecilia Lerma
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Roberto Parra-Saldivar
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- School of Engineering and Science, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64849, Mexico
| | - Dario R Lemos
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Guillermo A Llamas-Esperon
- Department of Interventional Cardiology, Hospital Cardiológica, Aguascalientes, Aguascalientes 20230, Mexico
| | - Jiawei Shi
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Li Li
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Anderson O Lobo
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, BioMatLab group, Material Science and Engineering Graduate Program, UFPI- Federal University of Piauí, Teresina, Piauí 64049-550, Brazil
| | - Andres A Fuentes-Baldemar
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Joseph V Bonventre
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Nianguo Dong
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
| |
Collapse
|
7
|
Wang X, Ruiz-Esparza GU. A NANOSTRUCTURED NON-NEWTONIAN DRUG DELIVERY BARRIER PREVENTS POSTOPERATIVE INTRAPERICARDIAL ADHESIONS. J Am Coll Cardiol 2021. [DOI: 10.1016/s0735-1097(21)04623-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Afewerki S, Bassous N, Harb SV, Corat MAF, Maharjan S, Ruiz-Esparza GU, de Paula MMM, Webster TJ, Tim CR, Viana BC, Wang D, Wang X, Marciano FR, Lobo AO. Engineering multifunctional bactericidal nanofibers for abdominal hernia repair. Commun Biol 2021; 4:233. [PMID: 33608611 PMCID: PMC7896057 DOI: 10.1038/s42003-021-01758-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 01/23/2021] [Indexed: 02/06/2023] Open
Abstract
The engineering of multifunctional surgical bactericidal nanofibers with inherent suitable mechanical and biological properties, through facile and cheap fabrication technology, is a great challenge. Moreover, hernia, which is when organ is pushed through an opening in the muscle or adjacent tissue due to damage of tissue structure or function, is a dire clinical challenge that currently needs surgery for recovery. Nevertheless, post-surgical hernia complications, like infection, fibrosis, tissue adhesions, scaffold rejection, inflammation, and recurrence still remain important clinical problems. Herein, through an integrated electrospinning, plasma treatment and direct surface modification strategy, multifunctional bactericidal nanofibers were engineered showing optimal properties for hernia repair. The nanofibers displayed good bactericidal activity, low inflammatory response, good biodegradation, as well as optimal collagen-, stress fiber- and blood vessel formation and associated tissue ingrowth in vivo. The disclosed engineering strategy serves as a prominent platform for the design of other multifunctional materials for various biomedical challenges.
Collapse
Affiliation(s)
- Samson Afewerki
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Health Sciences and Technology, Harvard University ‒ Massachusetts Institute of Technology, Cambridge, MA, USA.
| | - Nicole Bassous
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| | - Samarah Vargas Harb
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
- Institute of Chemistry, São Paulo State University (UNESP), Araraquara, São Paulo, Brazil
| | - Marcus Alexandre F Corat
- Multidisciplinary Center for Biological Research, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
| | - Sushila Maharjan
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Health Sciences and Technology, Harvard University ‒ Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Health Sciences and Technology, Harvard University ‒ Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Mirian M M de Paula
- Multidisciplinary Center for Biological Research, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
| | - Thomas J Webster
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| | | | - Bartolomeu Cruz Viana
- LIMAV - Interdisciplinary Laboratory for Advanced Materials, Materials Science & Engineering Graduate Program, UFPI - Federal University of Piaui, Teresina, Piaui, Brazil
- Department of Physics, Federal University of Piaui, Teresina, Piaui, Brazil
| | - Danquan Wang
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| | - Xichi Wang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Health Sciences and Technology, Harvard University ‒ Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Fernanda Roberta Marciano
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
- Department of Physics, Federal University of Piaui, Teresina, Piaui, Brazil
| | - Anderson Oliveira Lobo
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Health Sciences and Technology, Harvard University ‒ Massachusetts Institute of Technology, Cambridge, MA, USA.
- LIMAV - Interdisciplinary Laboratory for Advanced Materials, Materials Science & Engineering Graduate Program, UFPI - Federal University of Piaui, Teresina, Piaui, Brazil.
- Department of Chemistry, Massachusetts Institute of Technology, MIT, Cambridge, MA, USA.
| |
Collapse
|
9
|
Afewerki S, Wang X, Ruiz-Esparza GU, Tai CW, Kong X, Zhou S, Welch K, Huang P, Bengtsson R, Xu C, Strømme M. Combined Catalysis for Engineering Bioinspired, Lignin-Based, Long-Lasting, Adhesive, Self-Mending, Antimicrobial Hydrogels. ACS Nano 2020; 14:17004-17017. [PMID: 33306909 DOI: 10.1021/acsnano.0c06346] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
The engineering of multifunctional biomaterials using a facile sustainable methodology that follows the principles of green chemistry is still largely unexplored but would be very beneficial to the world. Here, the employment of catalytic reactions in combination with biomass-derived starting materials in the design of biomaterials would promote the development of eco-friendly technologies and sustainable materials. Herein, we disclose the combination of two catalytic cycles (combined catalysis) comprising oxidative decarboxylation and quinone-catechol redox catalysis for engineering lignin-based multifunctional antimicrobial hydrogels. The bioinspired design mimics the catechol chemistry employed by marine mussels in nature. The resultant multifunctional sustainable hydrogels (1) are robust and elastic, (2) have strong antimicrobial activity, (3) are adhesive to skin tissue and various other surfaces, and (4) are able to self-mend. A systematic characterization was carried out to fully elucidate and understand the facile and efficient catalytic strategy and the subsequent multifunctional materials. Electron paramagnetic resonance analysis confirmed the long-lasting quinone-catechol redox environment within the hydrogel system. Initial in vitro biocompatibility studies demonstrated the low toxicity of the hydrogels. This proof-of-concept strategy could be developed into an important technological platform for the eco-friendly, bioinspired design of other multifunctional hydrogels and their use in various biomedical and flexible electronic applications.
Collapse
Affiliation(s)
- Samson Afewerki
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Xichi Wang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, United States
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, United States
| | - Cheuk-Wai Tai
- Department of Materials and Environmental Chemistry, Arrhenius Laboratory, Stockholm University, SE-10691 Stockholm, Sweden
| | - Xueying Kong
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Shengyang Zhou
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Ken Welch
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Ping Huang
- Department of Chemistry, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Rhodel Bengtsson
- Department of Materials Science and Engineering, Applied Mechanics, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Chao Xu
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| | - Maria Strømme
- Division of Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Box 35, 751 03 Uppsala, Sweden
| |
Collapse
|
10
|
Adans-Dester CP, Bamberg S, Bertacchi FP, Caulfield B, Chappie K, Demarchi D, Erb MK, Estrada J, Fabara EE, Freni M, Friedl KE, Ghaffari R, Gill G, Greenberg MS, Hoyt RW, Jovanov E, Kanzler CM, Katabi D, Kernan M, Kigin C, Lee SI, Leonhardt S, Lovell NH, Mantilla J, McCoy TH, Luo NM, Miller GA, Moore J, O'Keeffe D, Palmer J, Parisi F, Patel S, Po J, Pugliese BL, Quatieri T, Rahman T, Ramasarma N, Rogers JA, Ruiz-Esparza GU, Sapienza S, Schiurring G, Schwamm L, Shafiee H, Kelly Silacci S, Sims NM, Talkar T, Tharion WJ, Toombs JA, Uschnig C, Vergara-Diaz GP, Wacnik P, Wang MD, Welch J, Williamson L, Zafonte R, Zai A, Zhang YT, Tearney GJ, Ahmad R, Walt DR, Bonato P. Can mHealth Technology Help Mitigate the Effects of the COVID-19 Pandemic? IEEE Open J Eng Med Biol 2020; 1:243-248. [PMID: 34192282 PMCID: PMC8023427 DOI: 10.1109/ojemb.2020.3015141] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Accepted: 07/19/2020] [Indexed: 01/08/2023] Open
Abstract
Goal: The aim of the study herein reported was to review mobile health (mHealth) technologies and explore their use to monitor and mitigate the effects of the COVID-19 pandemic. Methods: A Task Force was assembled by recruiting individuals with expertise in electronic Patient-Reported Outcomes (ePRO), wearable sensors, and digital contact tracing technologies. Its members collected and discussed available information and summarized it in a series of reports. Results: The Task Force identified technologies that could be deployed in response to the COVID-19 pandemic and would likely be suitable for future pandemics. Criteria for their evaluation were agreed upon and applied to these systems. Conclusions: mHealth technologies are viable options to monitor COVID-19 patients and be used to predict symptom escalation for earlier intervention. These technologies could also be utilized to monitor individuals who are presumed non-infected and enable prediction of exposure to SARS-CoV-2, thus facilitating the prioritization of diagnostic testing.
Collapse
Affiliation(s)
- Catherine P Adans-Dester
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Stacy Bamberg
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Francesco P Bertacchi
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Brian Caulfield
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Kara Chappie
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Danilo Demarchi
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - M Kelley Erb
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Juan Estrada
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Eric E Fabara
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Michael Freni
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Karl E Friedl
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Roozbeh Ghaffari
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Geoffrey Gill
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Mark S Greenberg
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Reed W Hoyt
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Emil Jovanov
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Christoph M Kanzler
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Dina Katabi
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Meredith Kernan
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Colleen Kigin
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Sunghoon I Lee
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Steffen Leonhardt
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Nigel H Lovell
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Jose Mantilla
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Thomas H McCoy
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Nell Meosky Luo
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Glenn A Miller
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - John Moore
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Derek O'Keeffe
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Jeffrey Palmer
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Federico Parisi
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Shyamal Patel
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Jack Po
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Benito L Pugliese
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Thomas Quatieri
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Tauhidur Rahman
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Nathan Ramasarma
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - John A Rogers
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Guillermo U Ruiz-Esparza
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Stefano Sapienza
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Gregory Schiurring
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Lee Schwamm
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Hadi Shafiee
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Sara Kelly Silacci
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Nathaniel M Sims
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Tanya Talkar
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - William J Tharion
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - James A Toombs
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Christopher Uschnig
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Gloria P Vergara-Diaz
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Paul Wacnik
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - May D Wang
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - James Welch
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Lina Williamson
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Ross Zafonte
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Adrian Zai
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Yuan-Ting Zhang
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Guillermo J Tearney
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Rushdy Ahmad
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - David R Walt
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| | - Paolo Bonato
- Paolo Bonato is with the Department of Physical Medicine and RehabilitationHarvard Medical School at Spaulding Rehabilitation HospitalBostonMA02129USA.,Wyss InstituteHarvard UniversityCambridgeMA02138USA
| |
Collapse
|
11
|
Morais AIS, Wang X, Vieira EG, Viana BC, Silva-Filho EC, Osajima JA, Afewerki S, Corat MAF, Silva HS, Marciano FR, Ruiz-Esparza GU, Stocco TD, de Paula MMM, Lobo AO. Electrospraying Oxygen-Generating Microparticles for Tissue Engineering Applications. Int J Nanomedicine 2020; 15:1173-1186. [PMID: 32110015 PMCID: PMC7037066 DOI: 10.2147/ijn.s237334] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 01/14/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The facile preparation of oxygen-generating microparticles (M) consisting of Polycaprolactone (PCL), Pluronic F-127, and calcium peroxide (CPO) (PCL-F-CPO-M) fabricated through an electrospraying process is disclosed. The biological study confirmed the positive impact from the oxygen-generating microparticles on the cell growth with high viability. The presented technology could work as a prominent tool for various tissue engineering and biomedical applications. METHODS The oxygen-generated microparticles fabricated through electrospraying processes were thoroughly characterization through various methods such as X-ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR) analysis, and scanning electron microscopy (SEM)/SEM-Energy Dispersive Spectroscopy (EDS) analysis. RESULTS The analyses confirmed the presence of the various components and the porous structure of the microparticles. Spherical shape with spongy characteristic microparticles were obtained with negative charge surface (ζ = -16.9) and a size of 17.00 ± 0.34 μm. Furthermore, the biological study performed on rat chondrocytes demonstrated good cell viability and the positive impact of increasing the amount of CPO in the PCL-F-CPO-M. CONCLUSION This technological platform could work as an important tool for tissue engineering due to the ability of the microparticles to release oxygen in a sustained manner for up to 7 days with high cell viability.
Collapse
Affiliation(s)
- Alan IS Morais
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Xichi Wang
- Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan430022, People’s Republic of China
- Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Brigham & Women´s Hospital, Cambridge, MA02139, USA
- Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, MIT, Cambridge, MA02139, USA
| | - Ewerton G Vieira
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Bartolomeu C Viana
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
- Department of Physics, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Edson C Silva-Filho
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Josy A Osajima
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Samson Afewerki
- Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Brigham & Women´s Hospital, Cambridge, MA02139, USA
- Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, MIT, Cambridge, MA02139, USA
| | - Marcus AF Corat
- Multidisciplinary Center for Biological Research, University of Campinas (UNICAMP), Campinas13083-877, Brazil
| | - Heurison S Silva
- Department of Physics, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Fernanda R Marciano
- Department of Physics, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Brigham & Women´s Hospital, Cambridge, MA02139, USA
- Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, MIT, Cambridge, MA02139, USA
| | - Thiago D Stocco
- Multidisciplinary Center for Biological Research, University of Campinas (UNICAMP), Campinas13083-877, Brazil
- Faculty of Physiotherapy, Santo Amaro University, São Paulo04829-300, Brazil
| | - Mirian MM de Paula
- Multidisciplinary Center for Biological Research, University of Campinas (UNICAMP), Campinas13083-877, Brazil
| | - Anderson O Lobo
- LIMAV-Interdisciplinary Laboratory for Advanced Materials, Materials Science and Engineering Graduate Program, UFPI-Federal University of Piauí, Teresina, PICEP 64049-550, Brazil
| |
Collapse
|
12
|
Afewerki S, Bassous N, Harb S, Palo-Nieto C, Ruiz-Esparza GU, Marciano FR, Webster TJ, Furtado ASA, Lobo AO. Advances in dual functional antimicrobial and osteoinductive biomaterials for orthopaedic applications. Nanomedicine 2019; 24:102143. [PMID: 31862427 DOI: 10.1016/j.nano.2019.102143] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 12/02/2019] [Accepted: 12/04/2019] [Indexed: 12/15/2022]
Abstract
A vast growing problem in orthopaedic medicine is the increase of clinical cases with antibiotic resistant pathogenic microbes, which is predicted to cause higher mortality than all cancers combined by 2050. Bone infectious diseases limit the healing ability of tissues and increase the risk of future injuries due to pathologic tissue remodelling. The traditional treatment for bone infections has several drawbacks and limitations, such as lengthy antibiotic treatment, extensive surgical interventions, and removal of orthopaedic implants and/or prosthesis, all of these resulting in long-term rehabilitation. This is a huge burden to the public health system resulting in increased healthcare costs. Current technologies e.g. co-delivery systems, where antibacterial and osteoinductive agents are delivered encounter challenges such as site-specific delivery, sustained and prolonged release, and biocompatibility. In this review, these aspects are highlighted to promote the invention of the next generation biomaterials to prevent and/or treat bone infections and promote tissue regeneration.
Collapse
Affiliation(s)
- Samson Afewerki
- Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Brigham & Women´s Hospital, Cambridge, MA, USA; Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, MIT, Cambridge, MA, USA.
| | - Nicole Bassous
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| | - Samarah Harb
- Institute of Chemistry, São Paulo State University, Araraquara, - SP, Brazil
| | - Carlos Palo-Nieto
- Department of Medicinal Chemistry, BMC, Uppsala University, Uppsala, Sweden
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Harvard Medical School, Brigham & Women´s Hospital, Cambridge, MA, USA; Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, MIT, Cambridge, MA, USA
| | - Fernanda R Marciano
- Department of Physics, UFPI- Federal University of Piauí, Teresina, PI, Brazil
| | - Thomas J Webster
- Nanomedicine Laboratory, Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| | - André Sales Aguiar Furtado
- LIMAV - Interdisciplinary Laboratory for Advanced Materials, Department of Materials Engineering, UFPI- Federal University of Piauí, Teresina, PI, Brazil
| | - Anderson O Lobo
- LIMAV - Interdisciplinary Laboratory for Advanced Materials, Department of Materials Engineering, UFPI- Federal University of Piauí, Teresina, PI, Brazil; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
| |
Collapse
|
13
|
Paez-Mayorga J, Hernández-Vargas G, Ruiz-Esparza GU, Iqbal HMN, Wang X, Zhang YS, Parra-Saldivar R, Khademhosseini A. Bioreactors for Cardiac Tissue Engineering. Adv Healthc Mater 2019; 8:e1701504. [PMID: 29737043 DOI: 10.1002/adhm.201701504] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 02/22/2018] [Indexed: 02/05/2023]
Abstract
The advances in biotechnology, biomechanics, and biomaterials can be used to develop organ models that aim to accurately emulate their natural counterparts. Heart disease, one of the leading causes of death in modern society, has attracted particular attention in the field of tissue engineering. To avoid incorrect prognosis of patients suffering from heart disease, or from adverse consequences of classical therapeutic approaches, as well as to address the shortage of heart donors, new solutions are urgently needed. Biotechnological advances in cardiac tissue engineering from a bioreactor perspective, in which recapitulation of functional, biochemical, and physiological characteristics of the cardiac tissue can be used to recreate its natural microenvironment, are reviewed. Detailed examples of functional and preclinical applications of engineered cardiac constructs and the state-of-the-art systems from a bioreactor perspective are provided. Finally, the current trends and future directions of the field for its translation to clinical settings are discussed.
Collapse
Affiliation(s)
- Jesus Paez-Mayorga
- Tecnologico de Monterrey, School of Medicine and Health Sciences, Ave. Eugenio Garza Sada 2501, Monterrey, N. L., CP 64849, Mexico
| | - Gustavo Hernández-Vargas
- Tecnologico de Monterrey, School of Engineering and Sciences, Campus Monterrey, Ave. Eugenio Garza Sada 2501, Monterrey, N. L., CP 64849, Mexico
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Hafiz M N Iqbal
- Tecnologico de Monterrey, School of Engineering and Sciences, Campus Monterrey, Ave. Eugenio Garza Sada 2501, Monterrey, N. L., CP 64849, Mexico
| | - Xichi Wang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Yu Shrike Zhang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Roberto Parra-Saldivar
- Tecnologico de Monterrey, School of Engineering and Sciences, Campus Monterrey, Ave. Eugenio Garza Sada 2501, Monterrey, N. L., CP 64849, Mexico
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Microsystems Technologies Laboratories, MIT, Cambridge, MA, 02139, USA
| | - Ali Khademhosseini
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA
- Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA
- Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA
- California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA, 90095, USA
- College of Animal Bioscience and Technology, Department of Bioindustrial Technologies, Konkuk University, Hwayang-dong, Kwangjin-gu, Seoul, 143-701, Republic of Korea
- Center for Nanotechnology, King Abdulaziz University, Jeddah, 21569, Saudi Arabia
| |
Collapse
|
14
|
Miri AK, Nieto D, Iglesias L, Goodarzi Hosseinabadi H, Maharjan S, Ruiz-Esparza GU, Khoshakhlagh P, Manbachi A, Dokmeci MR, Chen S, Shin SR, Zhang YS, Khademhosseini A. Microfluidics-Enabled Multimaterial Maskless Stereolithographic Bioprinting. Adv Mater 2018; 30:e1800242. [PMID: 29737048 PMCID: PMC6133710 DOI: 10.1002/adma.201800242] [Citation(s) in RCA: 202] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Revised: 02/19/2018] [Indexed: 05/03/2023]
Abstract
A stereolithography-based bioprinting platform for multimaterial fabrication of heterogeneous hydrogel constructs is presented. Dynamic patterning by a digital micromirror device, synchronized by a moving stage and a microfluidic device containing four on/off pneumatic valves, is used to create 3D constructs. The novel microfluidic device is capable of fast switching between different (cell-loaded) hydrogel bioinks, to achieve layer-by-layer multimaterial bioprinting. Compared to conventional stereolithography-based bioprinters, the system provides the unique advantage of multimaterial fabrication capability at high spatial resolution. To demonstrate the multimaterial capacity of this system, a variety of hydrogel constructs are generated, including those based on poly(ethylene glycol) diacrylate (PEGDA) and gelatin methacryloyl (GelMA). The biocompatibility of this system is validated by introducing cell-laden GelMA into the microfluidic device and fabricating cellularized constructs. A pattern of a PEGDA frame and three different concentrations of GelMA, loaded with vascular endothelial growth factor, are further assessed for its neovascularization potential in a rat model. The proposed system provides a robust platform for bioprinting of high-fidelity multimaterial microstructures on demand for applications in tissue engineering, regenerative medicine, and biosensing, which are otherwise not readily achievable at high speed with conventional stereolithographic biofabrication platforms.
Collapse
Affiliation(s)
- Amir K Miri
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Daniel Nieto
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Microoptics and GRIN Optics Group, Applied Physics Department, Faculty of Physics, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | - Luis Iglesias
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Hossein Goodarzi Hosseinabadi
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Polymeric Materials Research Group, Department of Materials Science and Engineering, Sharif University of Technology, Tehran, 1458889694, Iran
| | - Sushila Maharjan
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Guillermo U Ruiz-Esparza
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Parastoo Khoshakhlagh
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
| | - Amir Manbachi
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Department of Biomedical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA
| | - Mehmet Remzi Dokmeci
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Shaochen Chen
- Department of NanoEngineering, University of California, San Diego, La Jolla, CA, 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, CA, 92093, USA
- Materials Science and Engineering Program, University of California, San Diego, La Jolla, CA, 92093, USA
| | - Su Ryon Shin
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Yu Shrike Zhang
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Ali Khademhosseini
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
- Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA
- Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, 90095, USA
- Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA
- California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA, 90095, USA
- Department of Bioindustrial Technologies, Konkuk University, Seoul, 143-701, Republic of Korea
| |
Collapse
|
15
|
Annabi N, Zhang YN, Assmann A, Sani ES, Cheng G, Lassaletta AD, Vegh A, Dehghani B, Ruiz-Esparza GU, Wang X, Gangadharan S, Weiss AS, Khademhosseini A. Engineering a highly elastic human protein-based sealant for surgical applications. Sci Transl Med 2017; 9:eaai7466. [PMID: 28978753 DOI: 10.1126/scitranslmed.aai7466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2016] [Revised: 05/11/2017] [Accepted: 08/17/2017] [Indexed: 04/28/2024]
Abstract
Surgical sealants have been used for sealing or reconnecting ruptured tissues but often have low adhesion, inappropriate mechanical strength, cytotoxicity concerns, and poor performance in biological environments. To address these challenges, we engineered a biocompatible and highly elastic hydrogel sealant with tunable adhesion properties by photocrosslinking the recombinant human protein tropoelastin. The subcutaneous implantation of the methacryloyl-substituted tropoelastin (MeTro) sealant in rodents demonstrated low toxicity and controlled degradation. All animals survived surgical procedures with adequate blood circulation by using MeTro in an incisional model of artery sealing in rats, and animals showed normal breathing and lung function in a model of surgically induced rat lung leakage. In vivo experiments in a porcine model demonstrated complete sealing of severely leaking lung tissue in the absence of sutures or staples, with no clinical or sonographic signs of pneumothorax during 14 days of follow-up. The engineered MeTro sealant has high potential for clinical applications because of superior adhesion and mechanical properties compared to commercially available sealants, as well as opportunity for further optimization of the degradation rate to fit desired surgical applications on different tissues.
Collapse
Affiliation(s)
- Nasim Annabi
- Department of Chemical Engineering, Northeastern University, Boston, MA 02115-5000, USA.
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
| | - Yi-Nan Zhang
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Alexander Assmann
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
- Department of Cardiovascular Surgery and Research Group for Experimental Surgery, Heinrich Heine University, Medical Faculty, Duesseldorf 40225, Germany
| | - Ehsan Shirzaei Sani
- Department of Chemical Engineering, Northeastern University, Boston, MA 02115-5000, USA
| | - George Cheng
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Antonio D Lassaletta
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Andrea Vegh
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Bijan Dehghani
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Guillermo U Ruiz-Esparza
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Xichi Wang
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Sidhu Gangadharan
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Anthony S Weiss
- School of Life and Environmental Sciences, University of Sydney, Sydney, New South Wales 2006, Australia
- Charles Perkins Centre, University of Sydney, Sydney, New South Wales 2006, Australia
- Bosch Institute, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139, USA.
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
- Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia
| |
Collapse
|
16
|
Leijten J, Seo J, Yue K, Santiago GTD, Tamayol A, Ruiz-Esparza GU, Shin SR, Sharifi R, Noshadi I, Álvarez MM, Zhang YS, Khademhosseini A. Spatially and Temporally Controlled Hydrogels for Tissue Engineering. Mater Sci Eng R Rep 2017; 119:1-35. [PMID: 29200661 PMCID: PMC5708586 DOI: 10.1016/j.mser.2017.07.001] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Recent years have seen tremendous advances in the field of hydrogel-based biomaterials. One of the most prominent revolutions in this field has been the integration of elements or techniques that enable spatial and temporal control over hydrogels' properties and functions. Here, we critically review the emerging progress of spatiotemporal control over biomaterial properties towards the development of functional engineered tissue constructs. Specifically, we will highlight the main advances in the spatial control of biomaterials, such as surface modification, microfabrication, photo-patterning, and three-dimensional (3D) bioprinting, as well as advances in the temporal control of biomaterials, such as controlled release of molecules, photocleaving of proteins, and controlled hydrogel degradation. We believe that the development and integration of these techniques will drive the engineering of next-generation engineered tissues.
Collapse
Affiliation(s)
- Jeroen Leijten
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Jungmok Seo
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Center for Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea
| | - Kan Yue
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Grissel Trujillo-de Santiago
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Microsystems Technologies Laboratories, MIT, Cambridge, 02139, MA, USA
- Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, CP 64849, Monterrey, Nuevo León, México
| | - Ali Tamayol
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Guillermo U. Ruiz-Esparza
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Su Ryon Shin
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Roholah Sharifi
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Iman Noshadi
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Mario Moisés Álvarez
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Microsystems Technologies Laboratories, MIT, Cambridge, 02139, MA, USA
- Centro de Biotecnología-FEMSA, Tecnológico de Monterrey at Monterrey, CP 64849, Monterrey, Nuevo León, México
| | - Yu Shrike Zhang
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139, USA
- Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea
- Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia
| |
Collapse
|
17
|
Assmann A, Vegh A, Ghasemi-Rad M, Bagherifard S, Cheng G, Sani ES, Ruiz-Esparza GU, Noshadi I, Lassaletta AD, Gangadharan S, Tamayol A, Khademhosseini A, Annabi N. A highly adhesive and naturally derived sealant. Biomaterials 2017; 140:115-127. [PMID: 28646685 PMCID: PMC5993547 DOI: 10.1016/j.biomaterials.2017.06.004] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 05/28/2017] [Accepted: 06/03/2017] [Indexed: 10/19/2022]
Abstract
Conventional surgical techniques to seal and repair defects in highly stressed elastic tissues are insufficient. Therefore, this study aimed to engineer an inexpensive, highly adhesive, biocompatible, and biodegradable sealant based on a modified and naturally derived biopolymer, gelatin methacryloyl (GelMA). We tuned the degree of gelatin modification, prepolymer concentration, photoinitiator concentration, and crosslinking conditions to optimize the physical properties and adhesion of the photocrosslinked GelMA sealants. Following ASTM standard tests that target wound closure strength, shear resistance, and burst pressure, GelMA sealant was shown to exhibit adhesive properties that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in small as well as translational large animal models proved GelMA to effectively seal large lung leakages without the need for sutures or staples, presenting improved performance as compared to fibrin glue, poly(ethylene glycol) glue and sutures only. Furthermore, high biocompatibility of GelMA sealant was observed, as evidenced by a low inflammatory host response and fast in vivo degradation while allowing for adequate wound healing at the same time. Combining these results with the low costs, ease of synthesis and application of the material, GelMA sealant is envisioned to be commercialized not only as a sealant to stop air leakages, but also as a biocompatible and biodegradable hydrogel to support lung tissue regeneration.
Collapse
Affiliation(s)
- Alexander Assmann
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA; Department of Cardiovascular Surgery and Research Group for Experimental Surgery, Heinrich Heine University, Medical Faculty, 40225, Duesseldorf, Germany
| | - Andrea Vegh
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Materials Science and Engineering, University of Toronto, Toronto, Ontario, M5S1A4, Canada
| | - Mohammad Ghasemi-Rad
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Sara Bagherifard
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Mechanical Engineering, Politecnico di Milano, Milan, 20156, Italy
| | - George Cheng
- Division of Pulmonary, Allergy, and Critical Care, Duke University Medical Center, Durham, NC, 27710, USA; Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
| | - Ehsan Shirzaei Sani
- Department of Chemical Engineering, Northeastern University, Boston, MA, 02115-5000, USA
| | - Guillermo U Ruiz-Esparza
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
| | - Iman Noshadi
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA; Department of Chemical Engineering, Northeastern University, Boston, MA, 02115-5000, USA
| | - Antonio D Lassaletta
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
| | - Sidhu Gangadharan
- Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
| | - Ali Tamayol
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA; Department of Physics, King Abdulaziz University, Jeddah, 21569, Saudi Arabia; Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul, 05029, Republic of Korea.
| | - Nasim Annabi
- Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA; Department of Chemical Engineering, Northeastern University, Boston, MA, 02115-5000, USA.
| |
Collapse
|
18
|
Yetisen AK, Jiang N, Tamayol A, Ruiz-Esparza GU, Zhang YS, Medina-Pando S, Gupta A, Wolffsohn JS, Butt H, Khademhosseini A, Yun SH. Paper-based microfluidic system for tear electrolyte analysis. Lab Chip 2017; 17:1137-1148. [PMID: 28207920 PMCID: PMC5433427 DOI: 10.1039/c6lc01450j] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
The analysis of tear constituents at point-of-care settings has a potential for early diagnosis of ocular disorders such as dry eye disease, low-cost screening, and surveillance of at-risk subjects. However, current minimally-invasive rapid tear analysis systems for point-of-care settings have been limited to assessment of osmolarity or inflammatory markers and cannot differentiate between dry eye subclassifications. Here, we demonstrate a portable microfluidic system that allows quantitative analysis of electrolytes in the tear fluid that is suited for point-of-care settings. The microfluidic system consists of a capillary tube for sample collection, a reservoir for sample dilution, and a paper-based microfluidic device for electrolyte analysis. The sensing regions are functionalized with fluorescent crown ethers, o-acetanisidide, and seminaphtorhodafluor that are sensitive to mono- and divalent electrolytes, and their fluorescence outputs are measured with a smartphone readout device. The measured sensitivity values of Na+, K+, Ca2+ ions and pH in artificial tear fluid were matched with the known ion concentrations within the physiological range. The microfluidic system was tested with samples having different ionic concentrations, demonstrating the feasibility for the detection of early-stage dry eye, differential diagnosis of dry eye sub-types, and their severity staging.
Collapse
Affiliation(s)
- Ali K Yetisen
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | - Nan Jiang
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. and State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, 122 Luoshi Road, Wuhan, 430070, China
| | - Ali Tamayol
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | - Guillermo U Ruiz-Esparza
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | - Yu Shrike Zhang
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | - Sofía Medina-Pando
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA.
| | - Aditi Gupta
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
| | - James S Wolffsohn
- Ophthalmic Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | - Haider Butt
- Nanotechnology Laboratory, School of Engineering, University of Birmingham, Birmingham B15 2TT, UK
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. and Department of Physics, King Abdulaziz University, Jeddah, 21589, Saudi Arabia and Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea
| | - Seok-Hyun Yun
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. and Harvard Medical School and Wellman Center for Photomedicine, Massachusetts General Hospital, 65 Landsdowne Street, Cambridge, Massachusetts 02139, USA
| |
Collapse
|
19
|
Brinegar K, K Yetisen A, Choi S, Vallillo E, Ruiz-Esparza GU, Prabhakar AM, Khademhosseini A, Yun SH. The commercialization of genome-editing technologies. Crit Rev Biotechnol 2017; 37:924-932. [PMID: 28100080 DOI: 10.1080/07388551.2016.1271768] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The emergence of new gene-editing technologies is profoundly transforming human therapeutics, agriculture, and industrial biotechnology. Advances in clustered regularly interspaced short palindromic repeats (CRISPR) have created a fertile environment for mass-scale manufacturing of cost-effective products ranging from basic research to translational medicine. In our analyses, we evaluated the patent landscape of gene-editing technologies and found that in comparison to earlier gene-editing techniques, CRISPR has gained significant traction and this has established dominance. Although most of the gene-editing technologies originated from the industry, CRISPR has been pioneered by academic research institutions. The spinout of CRISPR biotechnology companies from academic institutions demonstrates a shift in entrepreneurship strategies that were previously led by the industry. These academic institutions, and their subsequent companies, are competing to generate comprehensive intellectual property portfolios to rapidly commercialize CRISPR products. Our analysis shows that the emergence of CRISPR has resulted in a fivefold increase in genome-editing bioenterprise investment over the last year. This entrepreneurial movement has spurred a global biotechnology revolution in the realization of novel gene-editing technologies. This global shift in bioenterprise will continue to grow as the demand for personalized medicine, genetically modified crops and environmentally sustainable biofuels increases. However, the monopolization of intellectual property, negative public perception of genetic engineering and ambiguous regulatory policies may limit the growth of these market segments.
Collapse
Affiliation(s)
- Katelyn Brinegar
- a Harvard-MIT Division of Health Sciences and Technology , Massachusetts Institute of Technology , Cambridge , MA , USA.,b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA
| | - Ali K Yetisen
- a Harvard-MIT Division of Health Sciences and Technology , Massachusetts Institute of Technology , Cambridge , MA , USA.,b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA.,c Harvard Medical School and Wellman Center for Photomedicine , Massachusetts General Hospital , Cambridge , MA , USA
| | - Sun Choi
- b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA
| | - Emily Vallillo
- b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA
| | - Guillermo U Ruiz-Esparza
- a Harvard-MIT Division of Health Sciences and Technology , Massachusetts Institute of Technology , Cambridge , MA , USA.,b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA
| | - Anand M Prabhakar
- d Department of Radiology, Division of Cardiovascular Imaging , Harvard Medical School, Massachusetts General Hospital , Boston , MA , USA.,e The Wharton School of the University of Pennsylvania , Philadelphia , PA , USA
| | - Ali Khademhosseini
- a Harvard-MIT Division of Health Sciences and Technology , Massachusetts Institute of Technology , Cambridge , MA , USA.,b Biomaterials Innovation Research Center, Division of Biomedical Engineering , Brigham and Women's Hospital, Harvard Medical School , Cambridge , MA , USA.,f Wyss Institute for Biologically Inspired Engineering, Harvard University , Boston , MA , USA
| | - Seok-Hyun Yun
- a Harvard-MIT Division of Health Sciences and Technology , Massachusetts Institute of Technology , Cambridge , MA , USA.,c Harvard Medical School and Wellman Center for Photomedicine , Massachusetts General Hospital , Cambridge , MA , USA
| |
Collapse
|
20
|
Ruiz-Esparza GU, Segura-Ibarra V, Cordero-Reyes AM, Youker KA, Serda RE, Cruz-Solbes AS, Amione-Guerra J, Yokoi K, Kirui DK, Cara FE, Paez-Mayorga J, Flores-Arredondo JH, Guerrero-Beltrán CE, Garcia-Rivas G, Ferrari M, Blanco E, Torre-Amione G. A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur J Heart Fail 2016; 18:169-78. [PMID: 26749465 DOI: 10.1002/ejhf.463] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 09/24/2015] [Accepted: 11/12/2015] [Indexed: 12/15/2022] Open
Abstract
AIMS Ongoing inflammation and endothelial dysfunction occurs within the local microenvironment of heart failure, creating an appropriate scenario for successful use and delivery of nanovectors. This study sought to investigate whether cardiovascular cells associate, internalize, and traffic a nanoplatform called mesoporous silicon vector (MSV), and determine its intravenous accumulation in cardiac tissue in a murine model of heart failure. METHODS AND RESULTS In vitro cellular uptake and intracellular trafficking of MSVs was examined by scanning electron microscopy, confocal microscopy, time-lapse microscopy, and flow cytometry in cardiac myocytes, fibroblasts, smooth muscle cells, and endothelial cells. The MSVs were internalized within the first hours, and trafficked to perinuclear regions in all the cell lines. Cytotoxicity was investigated by annexin V and cell cycle assays. No significant evidence of toxicity was found. In vivo intravenous cardiac accumulation of MSVs was examined by high content fluorescence and confocal microscopy, with results showing increased accumulation of particles in failing hearts compared with normal hearts. Similar to observations in vitro, MSVs were able to associate, internalize, and traffic to the perinuclear region of cardiomyocytes in vivo. CONCLUSIONS Results show that MSVs associate, internalize, and traffic in cardiovascular cells without any significant toxicity. Furthermore, MSVs accumulate in failing myocardium after intravenous administration, reaching intracellular regions of the cardiomyocytes. These findings represent a novel avenue to develop nanotechnology-based therapeutics and diagnostics in heart failure.
Collapse
Affiliation(s)
- Guillermo U Ruiz-Esparza
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey N.L., México 64849.,Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Victor Segura-Ibarra
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey N.L., México 64849
| | - Andrea M Cordero-Reyes
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Keith A Youker
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Rita E Serda
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | - Ana S Cruz-Solbes
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Javier Amione-Guerra
- DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| | - Kenji Yokoi
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Dickson K Kirui
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Francisca E Cara
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Jesus Paez-Mayorga
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Jose H Flores-Arredondo
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | - Carlos E Guerrero-Beltrán
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Gerardo Garcia-Rivas
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA.,Department of Medicine, Weill Cornell Medical College New York, NY, 10021, USA
| | - Elvin Blanco
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, MS R7-360.5, Houston, TX 77030, USA
| | - Guillermo Torre-Amione
- Catedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey, Monterrey N.L., México 64710.,DeBakey Heart and Vascular Center, Houston Methodist Hospital, 6565 Fannin Street, Suite 1901, Houston, TX 77030, USA
| |
Collapse
|
21
|
Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther 2014; 22:1310-1319. [PMID: 24569835 DOI: 10.1038/mt.2014.27] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2013] [Accepted: 02/13/2014] [Indexed: 12/19/2022] Open
Abstract
Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct pharmacokinetic parameters of drugs. This study explores the synergistic potential of site-specific, colocalized delivery of rapamycin and paclitaxel through nanoparticle incorporation. Nanoparticle drug loading was accurately controlled, and synergistic drug ratios established in vitro. Precise drug ratios were maintained in tumors 48 hours after nanoparticle administration to mice, at levels twofold greater than liver and spleen, yielding superior antitumor activity compared to controls. Simultaneous and preferential in vivo delivery of rapamycin and paclitaxel to tumors yielded mechanistic insights into synergy involving suppression of feedback loop Akt phosphorylation and its downstream targets. Findings demonstrate that a same time, same place, and specific amount approach to combination chemotherapy by means of nanoparticle delivery has the potential to successfully translate in vitro synergistic findings in vivo. Predictive in vitro models can be used to determine optimum drug ratios for antitumor efficacy, while nanoparticle delivery of combination chemotherapies in preclinical animal models may lead to enhanced understanding of mechanisms of synergy, ultimately opening several avenues for personalized therapy.
Collapse
Affiliation(s)
- Elvin Blanco
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Takafumi Sangai
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Suhong Wu
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Angela Hsiao
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | - Guillermo U Ruiz-Esparza
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA; Escuela de Biotecnología y Alimentos y Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico
| | - Carlos A Gonzalez-Delgado
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA; Escuela de Biotecnología y Alimentos y Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico
| | - Francisca E Cara
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA
| | | | - Kurt W Evans
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Argun Akcakanat
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Ying Wang
- Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kim-Anh Do
- Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Funda Meric-Bernstam
- Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
| | - Mauro Ferrari
- Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas, USA.
| |
Collapse
|
22
|
Ruiz-Esparza GU, Flores-Arredondo JH, Segura-Ibarra V, Torre-Amione G, Ferrari M, Blanco E, Serda RE. The physiology of cardiovascular disease and innovative liposomal platforms for therapy. Int J Nanomedicine 2013; 8:629-40. [PMID: 23413209 PMCID: PMC3572823 DOI: 10.2147/ijn.s30599] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Heart disease remains the major cause of death in males and females, emphasizing the need for novel strategies to improve patient treatment and survival. A therapeutic approach, still in its infancy, is the development of site-specific drug-delivery systems. Nanoparticle-based delivery systems, such as liposomes, have evolved into robust platforms for site-specific delivery of therapeutics. In this review, the clinical impact of cardiovascular disease and the pathophysiology of different subsets of the disease are described. Potential pathological targets for therapy are introduced, and promising advances in nanotherapeutic cardiovascular applications involving liposomal platforms are presented.
Collapse
|
23
|
Blanco E, Sangai T, Hsiao A, Ruiz-Esparza GU, Ferrari M, Meric-Bernstam F. Abstract P6-11-03: Site-Specific, Concomitant Delivery of Rapamycin and Paclitaxel in Breast Cancer: Consequent Synergistic Efficacy Enhancement. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-11-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PI3k/Akt/mTOR) pathway is dysregulated in certain breast cancers. Ongoing clinical trials aim to therapeutically exploit this pathway through administration of rapamycin (RAP), an mTOR inhibitor, in combination with paclitaxel (PTX). However, actual drug synergy in clinical settings may not be fully realized due to disparate pharmacokinetic parameters of individual drug formulations, wherein drugs or their effects may never be present in the tumor at the same time. Our objective was to generate a nanoparticle platform capable of site-specifically delivering precise amounts of rapamycin and paclitaxel to breast tumors with hopes of increasing synergistic targeting of the PI3k/Akt/mTOR pathway.
Materials and Methods: Drug-containing nanoparticles composed of amphiphilic block copolymers of pegylated poly(∈-caprolactone) (PEG-PCL, MW = 5k-5k) were fabricated and nanoparticle size and drug loading efficiency was determined. In vitro growth inhibition of nanoparticle formulations of varying ratios was evaluated in MCF-7 and MDA-MB-468 breast cancer cells via sulforhodamine B assays, after which median-effect plot analyses and combination index calculations were conducted. Antitumor efficacy studies were performed in female nude mice bearing MDA-MB-468 tumors, in which nanoparticles were administered intravenously twice a week for the duration of three weeks. Biodistribution of drug-containing nanoparticles in extracted tumors were examined, as well as reverse phase protein array (RPPA) analysis to gain insights into site-specific synergy.
Results: Nanoparticles were spherical, with an average diameter of 9 nm. Both rapamycin and paclitaxel loaded favorably, allowing for customization of different ratios within nanoparticles. Combination indices demonstrated that a 3:1 ratio of RAP:PTX had the most synergy in MDA-MB-468 breast cancer cells in vitro, a synergy found to be preserved in vivo. Significant tumor regression (> 1.5 fold reduction from initial tumor volume) was observed in vivo upon administration of 3:1 RAP:PTX (15:5 mg/kg) nanoparticles. The precise ratio of rapamycin and paclitaxel (3:1) was found maintained in tumors 24 h after administration, an effect not achievable with free drug formulations. RPPA analysis demonstrated effective blocking of mTOR and Akt 24 h after administration of nanoparticles, key events in drug synergy.
Discussion: Site-specific delivery of synergistic agents in precisely-controlled drug ratios, possible through their incorporation into nanoparticles, was shown to be highly efficacious against breast tumors. Findings demonstrate the ability to deliver specific drug ratios to tumors, potentially precluding the need to administer maximal doses of both agents in order to achieve synergy, lessening patient side-effects. This study demonstrates the potential for prediction of in vivo therapeutic outcomes from in vitro synergistic findings. Nanoparticle delivery of drugs may also yield enhanced understanding of mechanisms of synergy between molecular-targeted drugs and traditional chemotherapeutics in vivo, resulting in novel and more efficacious treatment regimens.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-11-03.
Collapse
Affiliation(s)
- E Blanco
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Sangai
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Hsiao
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - GU Ruiz-Esparza
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Ferrari
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - F Meric-Bernstam
- The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
24
|
Blanco E, Hsiao A, Ruiz-Esparza GU, Landry MG, Meric-Bernstam F, Ferrari M. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol 2011; 5:492-503. [PMID: 22071376 PMCID: PMC5528328 DOI: 10.1016/j.molonc.2011.10.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Accepted: 10/13/2011] [Indexed: 01/14/2023] Open
Abstract
Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all-encompassing cell-killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle-based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.
Collapse
Affiliation(s)
- Elvin Blanco
- Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA
| | - Angela Hsiao
- Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA
| | | | - Matthew G. Landry
- Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA
| | - Funda Meric-Bernstam
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Mauro Ferrari
- Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA
| |
Collapse
|